Welcome to PsorVal.net | DermaSolve.net !

 

Your Source for Psor-Val | DermaSolve | Absorbase

 

 Serving Treatment Solutions for Psoriasis, Eczema, Dry Skin 

 

Providing News, Views, Tips and Tricks

along with great products for that   "Healthy You" 

 

Looking for Psor-Val Spray? Click here 


*Buy Psor-Val on Amazon* Click here


 

Now Shipping Psor-Val Spray World Wide

 International Clients - Click "We Ship Worldwide!"

MedWorm: Psoriasis

New Injectable for Plaque Psoriasis (Fri, 24 Apr 2015)
* Secukinumab (Cosentyx) is a newly approved recombinant human monoclonal antibody used to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy (or both). Secukinumab is administered subcutaneously, either by the patient or a provider. * The most common adverse effects include diarrhea, nasopharyngitis, and upper respiratory infections. Those who receive secukinumab may also have severe allergic reactions and have an increased risk of developing infections. (Source: AJN) MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.
>> read more

Transcutaneous delivery of leflunomide nanoemulgel: Mechanistic investigation into physicomechanical characteristics, in vitro anti-psoriatic and anti-melanoma activity (Fri, 24 Apr 2015)
Publication date: 20 June 2015 Source:International Journal of Pharmaceutics, Volume 487, Issues 1–2 Author(s): Swati Pund , Satish Pawar , Shashikant Gangurde , Deepali Divate The present study is a mechanistic validation of ‘proof of concept’ of effective topical delivery of leflunomide (LFD) nanoemulgel for localized efficient treatment of psoriatic lesions as well as melanoma affected skin regions. Hyperproliferation of keratinocytes in psoriasis and symbiotic relationship between keratinocytes and melanocytes, justifies the need of dual acting treatment. LFD is recently introduced significantly effective disease modifying anti-rheumatic drug and has been considered valuable for the treatment of psoriatic arthritis as well as melanoma. Current available treatments for psoriasis...
>> read more

Secretion, blood levels and cutaneous expression of TL1A in psoriasis patients (Fri, 24 Apr 2015)
TL1A is a TNF‐like cytokine which has been shown to co‐stimulate TH1 and TH17 responses during chronic inflammation. The expression of this novel cytokine has been investigated in inflammatory disorders like rheumatoid arthritis and inflammatory bowel disease, but little is known about expression and induction in psoriasis. Indeed, the pathogenesis in psoriasis is still not fully understood and it is speculated that cytokines other than TNF‐α are important in subsets of patients. Also, for patients with severe disease that are treated with systemic anti‐TNF‐α blockade, novel candidates to be used as disease and response biomarkers are of high interest. Here, we demonstrate TL1A expression in biopsies from psoriatic lesions. Also, we investigated spontaneous and induced TL1A sec...
>> read more

Researchers will evaluate ustekinumab’s ability to treat lupus (Thu, 23 Apr 2015)
The effectiveness of treating lupus with a drug approved for treating plaque psoriasis and active psoriatic arthritis will be tested in a clinical study. The study, which will be conducted by the Alliance for Lupus Research and Janssen Research & Development, LLC, will evaluate the drug,... (Source: Skin and Allergy News)
>> read more

The vitamin D analogue calcipotriol reduces the frequency of CD8+IL‐17+ T cells in psoriasis lesions (Thu, 23 Apr 2015)
ConclusionOur findings show that the vitamin D analogue calcipotriol reduces the frequency of CD8+IL‐17+ T cells in psoriasis lesions concomitant with clinical improvement.(247 words)This article is protected by copyright. All rights reserved. (Source: Scandinavian Journal of Immunology)
>> read more

Complementary and Alternative Medicine for Psoriasis: What the Dermatologist Needs to Know (Wed, 22 Apr 2015)
Abstract Complementary and alternative medicine (CAM) use is common among patients with psoriasis. CAM modalities include traditional Chinese medicine (TCM), herbal therapies, dietary supplements, climatotherapy, and mind/body interventions. In this review, evidence from clinical trials investigating the efficacy of CAM for psoriasis is reviewed. There is a large amount of evidence from controlled trials that have shown that the combination of TCM with traditional therapies for psoriasis is more efficacious than traditional therapies alone. Herbal therapies that have the most evidence for efficacy are Mahonia aquifolium and indigo naturalis, while there is a smaller amount of evidence for aloe vera, neem, and extracts of sweet whey. Dietary supplementation in patients with psorias... MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.
>> read more

Athlete’s foot cream could also treat multiple sclerosis (Wed, 22 Apr 2015)
Conclusion This laboratory and mouse study has identified two drugs currently used for skin conditions – miconazole and clobetasol – that showed promise for treatment of conditions caused by myelin damage, such as MS. If a drug is already licensed for another condition in humans, this can make progress to human trials quicker if it is going to be given at a similar dose and in the same way. However, as the researchers point out, these two drugs are licensed for use on the skin – not to be taken orally or injected into the system. This means more work will be needed to ensure the drugs are safe enough to be used in this way in humans. The drugs' chemical structures may need to be modified to make them work efficiently and reduce side effects. Existing MS treatments act by dampening d...
>> read more

Radical Improvement of Signs and Symptoms in Systemic Lupus Erythematosus when Treated with Hemodiafiltration with Endogenous Reinfusion Dialysis (Tue, 21 Apr 2015)
We present the case of a 42-year-old woman with lupus nephritis accompanied by periods of exacerbation of SLE, with necrotic-like skin lesions, psoriatic arthritis without skin psoriasis, purpura of the lower limb, petechial rash, joint pain, fever, eyelid edema with bilateral conjunctival hyperemia and itching. The patient underwent a dialytic treatment of hemodiafiltration with endogenous reinfusion. The technique uses the super-high-flux membrane Synclear 02 (SUPRA treatment) coupled with an adsorbent cartridge that has affinity for many toxins and mediators. Fever and joint pain were immediately reduced after treatment and, subsequently, there was a notable reduction of the skin damage. Prednisone and immunosuppressive drugs were gradually reduced until complete suspension. High-perfor...
>> read more

Psoriatic arthritis: It's as easy as “PSA” (Tue, 21 Apr 2015)
Psoriatic arthritis (PsA) is a chronic inflammatory arthritis that occurs in 7% to 48% of individuals with psoriasis.1,2 The prompt and accurate diagnosis of PsA is essential to avoid irreversible joint damage and disability.1,3 The diagnosis of PsA is often delayed up to 2 years according to a recent National Psoriasis Foundation survey and other studies, and PsA screening has become a more prominent issue.2,4,5 The evidence of delayed diagnosis and underdiagnosis of PsA—in addition to our increased understanding of the long-term consequences of untreated PsA—have also contributed to the increased interest in PsA screening. (Source: Journal of the American Academy of Dermatology)
>> read more

Psoriatic Arthritis Under a Proteomic Spotlight: Application of Novel Technologies to Advance Diagnosis and Management (Tue, 21 Apr 2015)
Abstract Psoriatic arthritis is a form of inflammatory arthritis that is frequently associated with psoriasis. Individuals with this disease present with heterogeneous clinical manifestations, making it challenging to diagnose and select optimal treatment strategies. Perhaps, not unsurprisingly, there are currently no molecular diagnostic or prognostic tests to confirm if a patient has the disease or predict how they may respond to therapy. Instead, a range of classification criteria have been developed, and the experience of the treating clinician is heavily relied upon. It is therefore widely accepted that there is a significant and as yet unmet need for effective molecular markers in psoriatic arthritis. Protein mediators drive disease pathogenesis and, therefore, represent lo...
>> read more

 

Scan our QR Code to your Smart Phone / iPhone Users download QR Reader from Tap Media http://www.TapMedia.co.uk 

Real Time Web Analytics


International Clients, After adding products to Cart - Refresh your browser if you do not see the "International Checkout" Button

Psor-Val Zinc Spray, DermaSolve Psoriasis Care Products and

Absorbase Cream for Moisturizing Skin Care.

 

Treatment Solutions and Products for Psoriasis, Eczema, Dry Skin. Natural Care for that Healthy You!